Preferred Label : Sutimlimab;
NCIt synonyms : Immunoglobulin G4, Anti-(Human Complement C1S) (Humanized Mouse Monoclonal TNT009
Gamma4-chain), Disulfide with Humanized Mouse Monoclonal TNT009 Kappa-chain, Dimer; WHO 10757; Sutimlimab-jome;
NCIt definition : A humanized monoclonal immunoglobulin G4 (IgG4) antibody directed against human compliment
factor C1s, with potential immunomodulatory activity. Upon intravenous administration,
sutimlimab targets, binds to and blocks the activity of C1s, a portion of the C1 complex,
preventing enzymatic action on its substrates, C4 and C2, and inhibiting the formation
of C3 convertase. By selectively targeting the classical complement pathway (CP),
the function of both the alternative and lectin pathways are preserved. C1s, a serine
protease, is responsible for the propagation of the classical complement pathway of
the immune system; dysregulation of the classical compliment cascade plays a key role
in a variety of complement-mediated disorders.;
UNII : GNWE7KJ995;
CAS number : 2049079-64-1;
Drug name : Enjaymo;
Molecule name : BIVV-009; BIVV 009; IPN 009; TNT009; IPN-009;
NCI Metathesaurus CUI : CL554352;
Codes from synonyms : 61962;
Origin ID : C153093;
UMLS CUI : C4727016;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
